The lesions are not the problem. They are the signal. Beneath every recurring boil, sinus tract, and scar is a pattern of internal dysfunction that has gone unaddressed — until now.
Dr. Adil Moulanchikkal, BAMS · Founder, EPOH · Creator, EPOH HS Protocol™
300 HS cases in remission with the EPOH HS Protocol
Most patients who reach EPOH have already been through multiple courses of antibiotics. Some have undergone surgery. Many have tried steroids, topical treatments, and dietary changes they found online. And still — the boils return.
This is not a failure of willpower or hygiene. It is a predictable outcome of treating the visible symptom while the internal process that drives it continues, uninterrupted.
HS follows patterns. Each flare is not a new event — it is a continuation of the same underlying process expressing itself through the same vulnerable areas. Until that process is addressed, recurrence is not a possibility. It is a certainty.
"If it keeps coming back, it means the root cause has not been addressed."
● Antibiotics that work temporarily, then stop working
● Surgery on one site, new lesions appearing elsewhere
● Flares triggered by stress, hormonal shifts, or diet changes
● Escalating severity — lesions merging, forming tunnels
● Doctors explaining the symptom, not the cause
● The condition beginning to affect work, relationships, daily life
Average duration before patients reach EPOH — after exhausting conventional options
More likely to recur when treated as a skin condition rather than a systemic one
HS cases in remission with the EPOH HS Protocol — across Hurley stages I through III
HS is consistently managed as a localised skin problem — infections treated with antibiotics, lesions removed by surgery. This is why it keeps returning. The condition originates in a different place entirely.
In Ayurveda, this is understood as Ama accumulation and Rakta Dushti — toxin load and blood-level inflammation — driving the condition from within, long before it appears on the skin.
Ayurvedic Clinical Lens
Hidradenitis Suppurativa develops when five interconnected biological systems lose their coordination over time. The skin lesions that appear — the nodules, abscesses, sinus tracts — are the final, visible expression of a process that has been building internally.
When digestion weakens, inflammatory load builds in the bloodstream. When hormones shift — particularly in women with PCOS or androgen excess — follicular activity intensifies. When immune signalling misfires, the inflammatory response becomes self-sustaining. When lymphatic drainage slows, toxins accumulate in the precise areas where HS most commonly appears.
Each of these systems feeds into the others. Treating any one of them in isolation — or worse, treating only the lesion itself — addresses a small part of a much larger process.
The EPOH approach begins by identifying which of these systems is dominant in a given patient, and in what pattern. This is what makes a personalised evaluation essential — because no two patients have the same internal profile, even when their lesions look identical.
The 5-System HS Framework
Gut Dysfunction
Weakened digestion → inflammatory toxin buildup → immune activation
Hormonal Imbalance
Androgen excess, insulin resistance, PCOS link — drives follicular activity
Immune Dysregulation
Overactive inflammatory response — misfiring immune signalling
Lymphatic Stagnation
Poor drainage in axilla, groin, inframammary — toxin accumulation at lesion sites
Follicular & Tissue Vulnerability
Structural blockage + rupture → abscess formation → sinus tract development
All five systems interact. In most patients, multiple systems are involved simultaneously. This is why single-system treatment produces incomplete results.
Not a fixed protocol — a structured logic. Each phase addresses a specific layer of the disease. Sequence matters. Skipping phases is why most approaches produce temporary results.
Before healing can begin, the existing cycle of inflammation must be interrupted. This phase focuses on reducing the active inflammatory burden — cooling the internal fire that sustains lesion formation.
Gut health, hormonal balance, and metabolic function are addressed in a specific sequence. The internal drivers identified in evaluation become the targets. Personalisation is highest in this phase.
Accumulated inflammatory toxins are systematically cleared through enhanced elimination pathways. This is not a generic cleanse — it is targeted removal of the specific toxin load identified in each patient.
Once internal correction is underway, attention turns to the damaged tissue — healing sinus tracts, reducing scarring, and restoring the structural integrity of the skin and follicular environment.
The final phase builds long-term resilience. Immunity is strengthened, lifestyle alignment is established, and the conditions that originally allowed HS to develop are systematically removed.
EPOH is not the right starting point for every patient. Understanding who benefits most prevents wasted time and sets honest expectations from the beginning.
Most patients who benefit have been dealing with HS for 3–10 years and have not found lasting relief through conventional treatment.
If you are in an acute crisis, please seek emergency care first. EPOH works best as a structured, long-term approach — not crisis management.
Many patients with long-standing HS consult Dr. Adil after exhausting multiple treatment pathways without lasting relief. The EPOH HS Protocol™ was developed through clinical observation of patient patterns — not from a textbook. It reflects what actually drives recurrence, progression, and, in the right cases, reversal.
Years of Clinical Practice
Focused Ayurvedic clinical practice, with a growing specialisation in complex, recurrent inflammatory conditions including HS.
Primary Patient Profile
A significant proportion of patients present at advanced stages — with sinus tracts, chronic drainage, and documented treatment resistance. This is where the protocol was stress-tested.
Addressed Simultaneously
Gut, hormones, immunity, lymphatic drainage, and tissue repair — evaluated and addressed as an interconnected system, not in isolation.
These are not testimonials. They are representative patterns — the recurring combinations of history, triggers, and disease behaviour that appear consistently across patients.
Lesions consistently worsening in the 7–10 days before menstruation. Multiple antibiotic courses. Hormones not formally evaluated. Surgery recommended but declined. Gut symptoms — bloating, irregular bowel function — present but dismissed as unrelated.
Hormonal and gut axes addressed together. Flare frequency reduced significantly over 4–6 months of structured treatment.
Two surgical excisions in three years. New lesions forming adjacent to healed surgical sites. Metabolic indicators — elevated insulin, weight gain around the abdomen — present and unaddressed. Antibiotics no longer effective.
Metabolic correction and detoxification targeted. No new surgical lesions in the treatment period. Existing scarring partially improved.
Recurring nodules in groin and underarms for 18 months. No surgery yet. Stress-linked pattern — flares during exam periods, family disruption. Gut health poor. Hormones borderline. Seeking root-cause understanding before the condition advances.
Early-stage treatment most responsive. Stress regulation, gut correction, and lifestyle alignment initiated. Lesion frequency reduced within 8 weeks.
Clinical note: These patterns are illustrative, not predictive. Individual response to treatment varies based on disease stage, duration, and systemic profile. Results are not guaranteed. A personalised evaluation is required before any treatment approach is determined.
A structured evaluation identifies which internal systems are driving your condition — and what a personalised approach to correction would look like. This is not a consultation to sell a product. It is a clinical conversation about your specific pattern.
EPOH · Dr. Adil Moulanchikkal, BAMS · +91 88847 22246 · Personalised evaluation required before treatment commences
HS does not remain static. Without internal correction, the disease follows a predictable trajectory — from isolated nodules to interconnected tunnels to systemic involvement. Understanding this progression changes how treatment decisions are made.
Gut health is not peripheral to HS — in many patients, it is the primary driver of sustained inflammation. This article explains the mechanism by which gut dysfunction translates into repeated skin lesions.
Suppression — managing the flare — is not the same as correction. This article explains why treatment sequence matters more than treatment intensity, and why most approaches begin at the wrong layer.